Iron%252525252525252525252525252520sucrose

# Iron Sucrose ## Overview Iron sucrose is a parenteral iron complex used to replenish body iron stores in patients with iron deficiency anemia. It is a stable, non-dextran iron formulation, reducing the risk of anaphylaxis compared to older products like iron dextran. ## Primary Indications * Iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD), including dialysis-dependent (HDD-IDA) and non-dialysis-dependent (NDD-IDA) patients. * IDA in patients who are intolerant to or have failed oral iron therapy. ## Adult Dosing * **HDD-IDA:** 100 mg administered intravenously (IV) during each sequential dialysis session, up to a cumulative dose of 1,000 mg over 10 sessions. * **NDD-IDA:** 200 mg slow IV injection on 5 different occasions within a 14-day period (total 1,000 mg). * **Peritoneal Dialysis:** 300 mg slow IV injection at weeks 0 and 2, followed by 400 mg at week 4 (total 1,000 mg). * **Administration:** May be given as slow IV push (over 2–5 minutes) or diluted in 100 mL 0.9% NaCl and infused over 15 minutes. ## Pediatric Dosing * **HDD-IDA (≥2 years):** 0.5 mg/kg (max 100 mg) administered IV during each dialysis session over 10 sessions. * **NDD-IDA (≥2 years):** 0.5 mg/kg (max 100 mg) administered IV every 1–2 weeks for 5 doses. * *Note: Dosing strategies vary by institution; always consult local institutional formulary protocols.* ## Dose Adjustments * **Hepatic/Renal Impairment:** No specific dosage adjustment, but exercise caution in patients with history of iron overload. * **Hypersensitivity:** If a patient has a history of multiple drug allergies or asthma, exercise extreme caution; consider a test dose. ## Contraindications * Hypersensitivity to iron sucrose or any component of the formulation. * Evidence of iron overload (hemochromatosis, hemosiderosis). * Anemia not caused by iron deficiency. ## Adverse Effects * **Common:** Hypotension, nausea, muscle cramps, injection site reactions, headache. * **Serious:** Anaphylaxis/hypersensitivity reactions (bronchospasm, dyspnea, hypotension, angioedema), iron overload, syncope. ## Key Drug Interactions * **Oral Iron:** Parenteral iron should generally not be administered concomitantly with oral iron preparations as it may reduce the absorption of oral iron and increase risk of toxicity. * **ACE Inhibitors/ARBs:** May increase the risk of hypersensitivity reactions in patients receiving parenteral iron. ## Monitoring * **During Infusion:** Monitor for signs of hypersensitivity (hypotension, flushing, respiratory distress) for at least 30 minutes post-infusion. * **Laboratory:** Monitor hemoglobin (Hgb), hematocrit (Hct), serum ferritin, and transferrin saturation (TSAT) to assess response and prevent iron overload. ## Clinical Pearls * **Hypotension:** Often related to the rate of infusion; slowing the infusion rate can mitigate this. * **Safety:** Unlike low-molecular-weight iron dextran, iron sucrose does not require a formal test dose, but clinical vigilance during the first administration is mandatory. * **Stability:** Once diluted, use immediately. Do not mix with other medications. *** *Disclaimer: This information is for educational purposes and does not replace professional medical judgment. Always verify dosages, contraindications, and administration protocols against current institutional guidelines and the manufacturer’s package insert prior to prescribing or administering medication.*